- VALCYTE Powder for Oral Solution 50 mg/ml

Similar documents
VALCYTE Powder for Oral Solution

VALCYTE(R) Powder for Constitution

ACTIVASE Vials (100 mg)

PEGASYS(R) Prefilled Syringe (180 mcg/0.5 ml)

ACTEMRA(R) Sterile Concentrate for Injection (80 mg)

ACTEMRA(R) Sterile Concentrate for Injection (400 mg)

TECENTRIQ Vials (1,200 mg/20 ml)

AVASTIN(R) Vials (400 mg)

LUCENTIS(R) Vials (0.5 mg/0.05 ml)

XOLAIR(R) PFS (150 mg)

CATHFLO ACTIVASE(R) Vials (2 mg)

ANEXATE Ampoules 0.5 mg/5 ml

XOLAIR(R) Vials (150 mg)

GAZYVA(R) Vials (1,000 mg/40 ml)

ESBRIET(R) Capsules (267 mg)

DILATREND Tablets 6.25 mg

XOFLUZATM (Baloxavir Marboxil) Tablets 20mg

RITUXAN(R) Vials (100 mg/10 ml)

TAMIFLU(R) Capsules (75 mg)

TAMIFLU(R) Capsules (75 mg)

VALCYTE(R) F.C. Tablets (450 mg)

RITUXAN(R) Vials (100 mg/10 ml)

LEXOTAN Tablets 3 mg

ESBRIET F.C. Tablets 801 mg

INVIRASE(R) Capsules (200 mg)

HERCEPTIN HYLECTATM Vials (600 mg/5 ml) SC

KLONOPIN(R) Tablets (2.0 mg)

DORMICUM F.C. Tablets 15 mg

COPEGUS Tablets 200 mg

RITUXAN HYCELATM Vials (1,400 mg/23,400 Units per 11.7 ml)

DORMICUM Ampoules 5 mg/5 ml

ROACCUTANE Capsules 40 mg

HERCEPTIN(R) Vials (150 mg)

ROFERON-A PFS 3 M IU/0.5 ml

NeoRecormon PFS IU/0.6 ml

NeoRecormon PFS 2000 IU/0.3 ml

COTELLIC Tablets 20 mg

COPEGUS(R) F.C. Tablets (200 mg)

LEXOTAN Capsules 1.5 mg

ROACCUTANE Capsules 10 mg

Interferon alfa-2a Solution

XENICAL Capsules 120 mg

Vemurafenib MBP milled

Oseltamivir phosphate

XELODA(R) Tablets (500 mg)

XENICAL Capsules 120 mg

Fluorouracil Relevant identified uses of the substance or mixture and uses advised against. - pharmaceutical active substance (cytostatic)

TARCEVA(R) Tablets (25 mg)

KLONOPIN(R) Tablets (2 mg)

VALIUM Tablets 5 mg Relevant identified uses of the substance or mixture and uses advised against

VALIUM Tablets 10 mg

CELLCEPT(R) Powder for Oral Suspension

Isotretinoin Relevant identified uses of the substance or mixture and uses advised against

COTELLIC Tablets (20 mg)

CELLCEPT (R) Oral Suspension

TARCEVA Tablets 25 mg

LARIAM Tablets 250 mg

PEGASYS(R) Vials (0.135 mg/ml)

ANAPROX(R) Tablets (550 mg)

CELLCEPT(R) Powder for Oral Suspension

Citric acid anhydrous

CELLCEPT(R) Capsules (250 mg)

Orlistat Relevant identified uses of the substance or mixture and uses advised against

FUZEON Vials 90 mg Relevant identified uses of the substance or mixture and uses advised against

XELODA Tablets 125 mg

BACTRIM oral suspension 200/40mg/5ml

: PAD LOCK. SECTION 1: Identification. SECTION 2: Hazard(s) identification Identification Recommended use and restrictions on use

Trastuzumab Relevant identified uses of the substance or mixture and uses advised against

GLADE WAX MELTS (DAY SPA )

VALIUM(R) Tablets (10 mg)

PHENOL RED PHOTOMETER

Bath Salts Fine Scrub (Epsom)

Glade Wax Melts - Clean Linen

Revision Date 10/20/2017 SDS Number GEN_SOF Number : S.C. Johnson & Son, Inc Howe Street Racine WI

Mixture Name Product identifier % Classification (GHS-US)

Version: 2.2 Revision Date: Identification of the substance/mixture and of the company/undertaking

: Epsom Salt pure, technical

Raid Bed Bug Detector & Trap

WINDEX MULTI SURFACE ANTIBACTERIAL DISINFECTANT 2 (DIN )

: Phase II Paste A (with and without Fluoride)

GLADE CARPET & ROOM - CLEAN LINEN

Telephone : : : (24 H) Risk of serious damage to eyes.

: Consumer Care Center: UK Ireland

SCRUBBING BUBBLES BATHROOM CLEANER DISINFECTANT (DIN )

GLADE WAX MELTS (LAVENDER & VANILLA)

SAFETY DATA SHEET FM 2920 Rd. #615 Spring, TX Telephone: Telefax:

SCOTT Continuous Air Freshener Refill - Natural

SIGMA-ALDRICH. Material Safety Data Sheet Version 3.1 Revision Date 02/21/2011 Print Date 03/27/2011

: Bonide Bonide Liquid Orchid Food Concentrate

: Bonide Rot Stop Concentrate

SCRUBBING BUBBLES TOILET CLEANING GEL - ARCTIC SPLASH

1. IDENTIFICATION 2. HAZARDS IDENTIFICATION. Appearance Yellow liquid Physical State Liquid Odor Mild

ACS Material LLC LLC. Safety Data Sheet Single Layer Graphene. Version: 1.1 / EN Revision Date: 5/02/2017

WINDEX AUTO GLASS & INTERIOR

: SASE SIGNATURE DYE

GLADE PLUGINS SCENTED OIL (CLEAN LINEN )

Bonide Liquid Plant Food Safety Data Sheet according to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

SAFETY DATA SHEET Version 3.0 Revision Date 09/04/2017

: Vitrified Bond Grinding Wheels and Mounted Points Silicon Carbide

Transcription:

Safety Data Sheet VALCYTE(R) Powder for Oral Solution (50 mg/ml) SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product name Product code Synonyms VALCYTE(R) Powder for Oral Solution (50 mg/ml) SAP10090308 VALCYTE Powder for Oral Solution 50 mg/ml VALCYTE Dry Syrup 250 mg/5 ml 1.2. Relevant identified uses of the substance or mixture and uses advised against Use pharmaceutical active substance (virostatic) *1 1.3. Details of the supplier of the safety data sheet Company information Enquiries: Genentech, Inc. 1 DNA Way South San Francisco USACA 94080 United States of America Phone 001(650) 2251000 EMail info.sds@roche.com US Chemtrec phone: (800)4249300 Local representation: 1.4. Emergency telephone number Emergency telephone number US Chemtrec phone: (800)4249300 *1 SECTION 2: Hazards identification Emergency Overview Form Color granules white to slightly yellow Page: 1/9

Classification of the substance or mixture / Label elements GHS Classification Health Hazards: 3.5Germ cell mutagenicity (Category 1A) H340 May cause genetic defects. 3.6 Carcinogenicity (Category 1A) H350 May cause cancer. 3.7 Reproductive toxicity (Category 1A) H360FD May damage fertility. May damage the unborn child. 3.9 Specific target organ toxicity Repeated exposure (Category 1) H372 Causes damage to organs through prolonged or repeated exposure. Signalword: Danger Label: Precautionary statements: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust P281 Use personal protective equipment as required. P308 + P313 IF exposed or concerned: Get medical advice/attention. Other hazards SECTION 3: Composition/information on ingredients Characterization consisting of 46%, with the remainder consisting of excipients that are not classified as hazardous Ingredients Concentration GHSClassification (pure ingredient) 175865595 Fumaric acid 110178 ~ 46 % Combustible dust (No category), USH003 Germ cell mutagenicity (Category 1A), H340 Carcinogenicity (Category 1A), H350 Reproductive toxicity (Category 1A), H360FD Specific target organ toxicity Repeated exposure (Category 1), H372 ~ 2 % Serious eye damage/eye irritation (Category 2A), H319 For the full text of the Hphrases mentioned in this Section, see Section 16. Page: 2/9

SECTION 4: First aid measures 4.1. Description of first aid measures Eye contact Skin contact Inhalation Ingestion rinse immediately with tap water for 10 minutes open eyelids forcibly begin with medical treatment. remove immediately contaminated clothes, wash affected skin with water and soap do not use any solvents remove the casualty to fresh air and keep him/her calm get medical treatment summon a physician immediately 4.2. Most important symptoms and effects, both acute and delayed 4.3. Indication of any immediate medical attention and special treatment needed to physician treat symptomatically preserve blood and urine samples SECTION 5: Firefighting measures 5.1. Extinguishing media Suitable extinguishing media Flash point (liquid) Unsuitable extinguishing media water spray jet, dry powder, foam, carbon dioxide, adapt extinguishing media to surrounding fire conditions not applicable full water jet 5.2. Special hazards arising from the substance or mixture Specific hazards formation of toxic and corrosive combustion gases (ammonia, hydrogen chloride, nitrogen oxides) possible 5.3. Advice for firefighters Protection of firefighters precipitate gases/vapours/mists with water spray chemical incident emergency response unit with full protective equipment Page: 3/9

SECTION 6: Accidental release measures 6.1. Personal precautions, protective equipment and emergency procedures Personal precautions prevent any exposure 6.2. Environmental precautions Environmental protection do not allow to enter drains or waterways 6.3. Methods and material for containment and cleaning up Methods for cleaning up collect solids (avoid dust formation) and hand over to waste removal clean contaminated areas with little ethanol SECTION 7: Handling and storage 7.1. Precautions for safe handling Suitable materials aluminium, glass, stainless steel, enamel, polyethylene 7.2. Conditions for safe storage, including any incompatibilities Storage conditions below 30 C in closed containers protected from light Validity Packaging materials see "best use before" date stated on the label 36 months, 30 C, see "best use before" date stated on the label amber glass bottles with child resistant plastic closure polyethylene bag in metal drum SECTION 8: Exposure controls/personal protection 8.1. Control parameters Threshold value (Roche) air IOEL (Internal Occupational Exposure Limit): 0.008 mg/m3 *1 8.2. Exposure controls General protective and hygiene measures Respiratory protection instruction of employees mandatory cleanse skin thoroughly after work, apply skin cream Respiratory protection is recommended as a precaution to minimize exposure. Effective engineering controls are considered to be the primary means to control worker exposure. Respiratory protection should not substitute for feasible engineering controls. in case of open handling or accidental release: particle mask or respirator with independent air supply Page: 4/9

Hand protection Eye protection protective gloves (eg made of neoprene, nitrile or butyl rubber) safety glasses *1 SECTION 9: Physical and chemical properties 9.1. Information on basic physical and chemical properties Color Form white to slightly yellow granules Solubility 10 370 mg/l, ethanol 95 % *1 ~ 30 mg/l, acetone *1 ~ 2 990 mg/l, hexane *1 ~ 70 000 mg/l, water *1 Partition coefficient log P ow 0.009 (noctanol/buffer C) ph 6.9 *1 Melting temperature 175 C (with decomposition) *1 9.2. Other information Dissociation constant pk 1 7.6 *1 Solubility properties Hydrolysis hydrolytically unstable, in alkaline solution *1 *1 SECTION 10: Stability and reactivity 10.1. Reactivity 10.2. Chemical stability 10.3. Possibility of hazardous reactions Page: 5/9

10.4. Conditions to avoid Conditions to avoid warming humidity 10.5. Incompatible materials Materials to avoid strong oxidizing agents *1 10.6. Hazardous decomposition products tends to racemise and hydrolyse quickly in neutral and basic aqueous solution *1 *1 SECTION 11: Toxicological information 11.1. Information on toxicological effects Acute toxicity LD 50 > 2 000 mg/kg (oral, mouse) *1 Chronic toxicity NOAEL 2 mg/kg/d (oral, rat; 90 days) *1 Local effects skin: nonirritant (rabbit) *1 eye: irritant *2 skin: slightly irritating (rabbit) *2 Sensitization nonsensitizing (guinea pig) *1 Mutagenicity mutagenic *1 Carcinogenicity carcinogenic *3 Reproductive toxicity teratogenic and embryotoxic *3 may lower parental fertility *3 STOTsingle exposure STOTrepeated exposure Aspiration hazard causes testicular atrophy, renal and hematologic changes *1 Potential Health Effects Exposure: Inhalation, Ingestion, Skin contact, Eye contact Carcinogenicity: not listed by NTP, IARC or OSHA *1 *2 *3 Fumaric acid Ganciclovir Page: 6/9

SECTION 12: Ecological information 12.1. Toxicity Ecotoxicity barely toxic for planktonic crustaceans (Daphnia magna) EC 50 (48 h) > 1010 mg/l (average measured concentration) NOEC (48 h) 1010 mg/l (average measured concentration) *3 barely toxic for fish (rainbow trout) LC 50 (96 h) > 1020 mg/l (average measured concentration) NOEC (96 h) 1020 mg/l (average measured concentration) *3 barely toxic for fish (bluegill sunfish) LC 50 (96 h) > 1020 mg/l (average measured concentration) NOEC (96 h) 1020 mg/l (average measured concentration) *3 barely toxic for bluegreen algae (nominal concentration > 100 mg/l) (Nostoc sp.) NOEC (12 d) 1000 mg/l (FDA Technical Assistance Document No. 4.02) *3 barely toxic for microorganisms (bacteria, fungi, cyanobacteria in pure culture) NOEC 1000 mg/l *3 barely toxic for planktonic crustaceans (Daphnia magna) EC 50 (48 h) 212 mg/l *2 zebrafish LC 50 (48 h) 245 mg/l *2 Desmodesmus (=Scenedesmus) subspicatus EC 50 (72 h) 41 mg/l *2 12.2. Persistence and degradability Inherent biodegradability not inherently biodegradable 2 %, 28 days *3 evidence for mediumterm biodegradation in surface waters 34 %, 28 d (analogous to OECD 308, Transformation in natural water/sediment systems) *3 12.3. Bioaccumulative potential 12.4. Mobility in soil Mobility barely volatile (waterair) KH = 0.00000026 Pa*m3/mol (vapor pressure/water solubility) *3 12.5. Results of PBT and vpvb assessment Page: 7/9

12.6. Other adverse effects *2 *3 Fumaric acid Ganciclovir SECTION 13: Disposal considerations 13.1. Waste treatment methods Waste from residues incinerate in qualified installation with flue gas scrubbing observe local/national regulations regarding waste disposal return to supplier or hand over to authorized disposal company medicines should not be disposed of via wastewater SECTION 14: Transport information not classified as Dangerous Good according to the Dangerous Goods Regulations, proper shipping name nonregulated SECTION 15: Regulatory information 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture TSCA Status Reporting Requirements FDA Exemption not on inventory The United States Environmental Protection Agency (USEPA) has not established a Reportable Quantity (RQ) for releases of this material. In New Jersey, report all releases which are likely to endanger the public health, harm the environment or cause a complaint to the NJDEPE Hotline (16092925560) and to local officials. State and local regulations vary and may impose additional reporting requirements. SECTION 16: Other information Safetylab number BS6697 *1 Full text of HStatements referred to under section 3 H319 Causes serious eye irritation. H340 May cause genetic defects. H350 May cause cancer. H360FD May damage fertility. May damage the unborn child. H372 Causes damage to organs through prolonged or repeated exposure. USH003 May form combustible dust concentrations in the air Page: 8/9

Valganciclovir is a valyl ester prodrug of ganciclovir, which after oral administration is rapidly and extensively converted to ganciclovir during the absorption process *1 Edition documentation changes from previous version in sections 2, 3, 16 *1 The information in this safety data sheet is based on current scientific knowledge. It should not be taken as expressing or implying any warranty concerning product characteristics. Page: 9/9